A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory roleHydroxychloroquine Cures Type 2 Diabetes

I wanted to throw this in first. This is the type straightforward research paper that you find when those writing it are not paid off by Big Pharma.

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Conflict of interest statement: The authors declare no conflicts of interests.

“Hydroxychloroquine (HCQ), a commonly used antimalarial drug in rheumatic diseases, has shown favorable metabolic effects on both glucose control and lipid profiles.”

“HCQ as a treatment for her Sjogren syndrome in addition to a subtle yet measurable improvement in her lipid profile. An increasing body of evidence supports the beneficial impacts of HCQ in various ancillary conditions, including diabetes mellitus and dyslipidemia.”

Hydroxychloroquine Cures Type 2 Diabetes

“In September 2011, she was diagnosed with Sjogren syndrome and was started on HCQ 200 mg once daily. An improvement in her glycemic control as evidenced by self glucose monitoring was noted within 1 month of HCQ therapy, with no remarkable hypoglycemic episodes. Her glycated hemoglobin A1C (HbA1C) was successfully reduced to target in January 2011.”

“After reviewing the literature, our case seems to be the first case report of a patient with type 1 diabetes who had improvement in her glycemic control while on HCQ therapy.”

Hydroxychloroquine Cures Type 2 Diabetes

Hydroxychloroquine Cures Type 2 Diabetes

“Besides its glucose-lowering effect in patients with diabetes, lower fasting blood sugar levels [Penn et al. 2010], as well as hypoglycemia have also been reported with CQ and HCQ in subjects without diabetes.”

” Interestingly, HCQ lowers the incidence of developing diabetes mellitus. In a retrospective cohort of 1127 patients with RA, the use of HCQ was associated with a 71% reduction in the risk of incident diabetes [hazard ratio (HR) 0.29; 95% CI 0.09–0.95; p = 0.04]”

“Demonstrated a 77% reduced incidence of diabetes in patients with RA who took HCQ for longer than 4 years, after adjustment for risk factors of diabetes, disease activity and glucocorticoid use.”

“Similarly, another recent retrospective cohort of 13,905 patients with a diagnosis of either RA or psoriasis reported a lower incidence of diabetes among HCQ and tumor necrosis factor inhibitor users compared with other non-biological disease-modifying antirheumatic drugs (HR 0.54; 95% CI 0.36–0.80)”Hydroxychloroquine Cures Type 2 Diabetes

“The mechanism by which HCQ works to improve glycemic control in patients with type 1 diabetes is not known and our case seems to be the first case report in the literature.”

“A possible reduction in islet-cell autoimmunity by HCQ could be the underlying mechanism since our patient has longstanding type 1 diabetes with no insulin reserve and an effect on insulin resistance is less likely to be the underlying mechanism that led to the improvement in glycemic control.”

“Interestingly, changes in lipoproteins can be detected as early as 3 months after antimalarial therapy.”

“Reductions up to 54% in triglycerides (TGs), TC and apolipoprotein CIII levels have been reported in HCQ users in 18 women with mild or inactive SLE compared with nonusers. Furthermore, in a large longitudinal study involving 1260 patients with SLE, the use of antimalarials was negatively correlated with TC (p < 0.0001)”

“In addition, in a prospective randomized trial, Mundor and colleagues reported an overall increase of 15% in HDL-C in HCQ users in a population of patients with RA after 12 months of therapy compared with a decrement of 12% in patients treated with gold (p = 0.006)”Hydroxychloroquine Cures Type 2 Diabetes

“This case and review highlight the need to re-examine HCQ as a potential therapy for T2DM and consider its use especially in patients with rheumatism and diabetes.”

“Favorable lipid-lowering and antidiabetic properties of HCQ renders this drug an attractive medical option. Given the elevated cardiovascular risk associated with RA and SLE, the addition of HCQ to patients’ usual treatment could counteract the dyslipidemic effect of glucocorticoids, resulting in a potential minimization of atheroma progression and thus possibly lowering mortality due to cardiovascular diseases.”

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Conflict of interest statement: The authors declare no conflicts of interests.

journals.sagepub.com/doi/10.1177…

 

  • Hydroxychloroquine Cures Diabetes

Archives

  • September 2021 (3)
  • October 2020 (2)
  • September 2020 (15)
  • August 2020 (35)
  • July 2020 (31)